



Patent Application
Attorney Docket No. PC10139AMAG

#7/B
8/23/01
Jana

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 10th day of August, 2001.

By

Deanna L. Miller
(Signature of person mailing)
Deanna L. Miller

(Typed or printed name of person)

RECEIVE

AUG 21 2001

TECH CENTER 1600/2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:
N. HARPER ET AL.

APPLICATION NO.: 09/417,175

FILING DATE: OCTOBER 11, 1999

TITLE: SERTRALINE ORAL CONCENTRATE

Examiner: T. OH

Group Art Unit: 1623

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

REPLY AND AMENDMENT UNDER 37 C.F.R. 1.111 AND 1.121

In response to the Office Action dated February 13, 2001, Applicants make the following amendments and remarks. The period for response to the Office Action has been extended to August 13, 2001, pursuant to Applicants' Petition for Extension of Time filed herewith.

IN THE CLAIMS:

Please amend claim 1 to read as follows:

1. (Amended) A pharmaceutical composition which comprises:
an essentially nonaqueous, liquid concentrate for oral administration comprising about 15 to about 30 mg/ml of sertraline hydrochloride and pharmaceutically acceptable excipients; wherein the excipients are ethanol and glycerin in an amount of about 8 to about 20% ethanol (by weight) in glycerin.

Please cancel claims 2-6.

Please retain claims 7-11.

Please amend claim 12 to read as follows:

12. (Amended) A method of using an essentially nonaqueous, liquid concentrate of sertraline hydrochloride of claim 1 to prepare an aqueous solution of sertraline